Ganciclovir penetrates into the cerebrospinal fluid of an infant with congenital cytomegalovirus infection

Ital J Pediatr. 2015 Mar 31:41:26. doi: 10.1186/s13052-015-0132-8.

Abstract

Currently, there is no evidence whether ganciclovir, or its oral prodrug valganciclovir, penetrates into the cerebrospinal fluid of human infants treated for congenital cytomegalovirus infection. Here, we report a case study providing evidence that ganciclovir, administered as valganciclovir, reaches the infant's cerebrospinal fluid when used at the currently recommended dose for congenital cytomegalovirus infection.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antiviral Agents / administration & dosage
  • Antiviral Agents / pharmacology*
  • Antiviral Agents / therapeutic use*
  • Cytomegalovirus Infections / cerebrospinal fluid*
  • Cytomegalovirus Infections / congenital*
  • DNA, Viral / analysis
  • Female
  • Ganciclovir / administration & dosage
  • Ganciclovir / analogs & derivatives*
  • Ganciclovir / pharmacology
  • Ganciclovir / therapeutic use
  • Humans
  • Infant, Newborn
  • Pregnancy
  • Pregnancy Complications, Infectious
  • Valganciclovir

Substances

  • Antiviral Agents
  • DNA, Viral
  • Valganciclovir
  • Ganciclovir